Journal article
Changes in18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib
L Mileshkin, RJ Hicks, BGM Hughes, PLR Mitchell, V Charu, BJ Gitlitz, D Macfarlane, B Solomon, LC Amler, W Yu, A Pirzkall, BM Fine
Clinical Cancer Research | Published : 2011
Abstract
Purpose: Assessing clinical activity of molecularly targeted anticancer agents, especially in the absence of tumor shrinkage, is challenging. To evaluate on-treatment 18F-fluorodeoxyglucose (FDG) and/or 18F- fluorodeoxythymidine (FLT) positron emission tomography (PET) for this purpose, we conducted a prospective multicenter trial assessing PET response rates and associations with progression-free (PFS) and overall survival (OS) in 2nd/3rd-line non-small-cell lung cancer patients treated with erlotinib. Experimental Design: PET/computed tomography (CT) scans were conducted at baseline, day (d)14 and d56 after the first daily erlotinib dose, with diagnostic CT at baseline and d56 (all scans c..
View full abstractGrants
Funding Acknowledgements
B. Hughes, consultant, Roche; P. Mitchell, consultant, Roche; B. Solomon, consultant and speaker, Roche; V. Charu, commercial research grant, Genentech, Inc., other commercial support, Roche, Ltd, consultant, Genentech; L. Amler, W. Yu, A. Pirzkall, B. Fine, employees, Genentech, Inc. and hold stock with Roche, Ltd. The other authors disclosed no potential conflicts of interest.